| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MED | Common Stock | Options Exercise | $35,984 | +1,300 | +12% | $27.68 | 11,838 | 08 Mar 2024 | Direct | |
| transaction | MED | Common Stock | Sale | $51,233 | -1,300 | -11% | $39.41 | 10,538 | 08 Mar 2024 | Direct | |
| transaction | MED | Common Stock | Sale | $108,633 | -2,753 | -26% | $39.46 | 7,785 | 08 Mar 2024 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MED | Stock Option (Right to Buy) | Options Exercise | $0 | -1,300 | -100% | $0.000000* | 0 | 08 Mar 2024 | Common Stock | 1,300 | $27.68 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is an average price. These shares were acquired in multiple transactions at prices ranging from $39.38 to $39.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote. |
| F2 | The reporting person received 5,000 stock options on February 4, 2016 pursuant to the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan. These options vested in three equal annual installments beginning on February 4, 2017. |